Login to Your Account



Surprising Iressa Blowup Sends OSI Stock Skyward

By Randall Osborne


Monday, December 20, 2004
With AstraZeneca plc's failure of Iressa in non-small-cell lung cancer, the winners were Genentech Inc. and partner OSI Pharmaceuticals Inc. and their drug Tarceva - also an epidermal growth factor inhibitor - which was approved for the indication last month. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription